Skip to Main Content

Paper Details

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
Clin Cancer Res
95
2017
AKT, AKT isoforms, AKT2, CCNE1, CCNE1-amplified HGSC, CCNE1-amplified cancers, CCNE1-amplified tumors, CDK2, Cyclin, Cyclin E1, Cyclin-Dependent Kinase 2, HGSC, HGSC cell lines, amplicon, dinaciclib, fallopian tube secretory cells, high-grade serous ovarian cancer, mutant TP53, patients, primary tumors, siRNA, untransformed fallopian tube secretory cells
Author NameAffiliation
George Au-YeungPeter MacCallum Cancer Centre
George Au-YeungUniversity of Melbourne
George Au-YeungPeter MacCallum Cancer Centre
George Au-YeungUniversity of Melbourne
Richard B PearsonPeter MacCallum Cancer Centre
Richard B PearsonUniversity of Melbourne
Richard B PearsonUniversity of Melbourne
Ronny DrapkinPenn Ovarian Cancer Research Center, University of Pennsylvania Perelman School of Medicine
Ronny DrapkinPenn Ovarian Cancer Research Center, University of Pennsylvania Perelman School of Medicine
Dariush EtemadmoghadamPeter MacCallum Cancer Centre
Dariush EtemadmoghadamUniversity of Melbourne
Dariush EtemadmoghadamUniversity of Melbourne
Dariush EtemadmoghadamPeter MacCallum Cancer Centre
Dariush EtemadmoghadamUniversity of Melbourne
Dariush EtemadmoghadamUniversity of Melbourne
David D L BowtellPeter MacCallum Cancer Centre
David D L BowtellUniversity of Melbourne
David D L BowtellUniversity of Melbourne
David D L BowtellKinghorn Cancer Centre, Garvan Institute for Medical Research
David D L BowtellPeter MacCallum Cancer Centre
David D L BowtellUniversity of Melbourne
David D L BowtellUniversity of Melbourne
David D L BowtellKinghorn Cancer Centre, Garvan Institute for Medical Research
  • 1 - 23

Datasets

Release 1.2